Protalix BioTherapeutics, Inc. (DE) (PLX) Earnings Call Analysis

AMEX · Healthcare · Biotechnology

Earnings Reports

• Protallix (PLX) Q1 2026: $25M Milestone Bolsters Cash, Sets Stage for Elfabio Uptake
  May 13, 2026
• Protallix (PLX) Q4 2025: $25M Milestone Bolsters Cash, EU Dosing Win Reshapes Fabry Trajectory
  March 18, 2026
• NOVA (NVMI) Q4 2024: Advanced Packaging Doubles to 15% of Product Revenue, Extending Share Gains
  November 13, 2025
• Protalix (PLX) Q2 2025: R&D Spend Doubles as PRX115 Phase II Launch Nears
  August 14, 2025

Browse all companies